The UC Hematologic Malignancies Consortium (UCHMC) is a collaboration of academic clinicians across UC’s five NCI-designated Comprehensive Cancer Centers and UCSF Fresno, and its mission is to conduct clinical research on rare blood cancers with enough patients to make a difference in the science that can lead to precision treatment.

UCHMC Clinical Trials

The following UCHMC-initiated studies are now underway. Click the links to learn more about each clinical trial including eligibility requirements.

Leukemia

CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
Locations: UC Davis Comprehensive Cancer Center, UC Irvine Chao Family Comprehensive Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
Locations: UC Davis Comprehensive Cancer Center, UCLA Jonsson Comprehensive Cancer Center

Current leukemia clinical trials across the UC system
 

Lymphoma

A Study of Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
Locations: UC Davis Comprehensive Cancer Center, UC Irvine Chao Family Comprehensive Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Locations: UC Davis Comprehensive Cancer Center, UCLA Jonsson Comprehensive Cancer Center

A Study of Chemotherapy Drugs CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Lymphoma
Location: UC Davis Comprehensive Cancer Center

A Study of Brentuximab Vedotin and Bendamustine for the Treatment of Follicular Lymphoma
Location: UC Davis Comprehensive Cancer Center

Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
Location: UC Davis Comprehensive Cancer Center

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma
Location: UCLA Jonsson Comprehensive Cancer Center

Current lymphoma clinical trials across the UC system
 

Multiple Myeloma

Current multiple myeloma clinical trials across the UC system

Upcoming events

Check back for updates on future events.

Funding Opportunities

The UC Hematologic Malignancies Consortium supports projects that encourage collaboration among UC campuses. For additional information, contact Jesika Reiner.

About us

The UCHMC aims to make treatment of rare blood cancers more accessible for a larger and more diverse patient population, through the expansion of multi-site clinical trials led by physician scientists across the UC system.

Leadership

Matthew Joseph Wieduwilt, M.D., Ph.D. (Chair)

UC Davis Comprehensive Cancer Center
Joseph Tuscano, M.D.
UC Irvine Chao Family Comprehensive Cancer Center
Deepa Jeyakumar, M.D.
UCLA Jonsson Comprehensive Cancer Center
Gary Schiller, M.D.
UC San Diego Moores Cancer Center
Ben Heyman, M.D.
UCSF Helen Diller Family Comprehensive Cancer Center
Lloyd Damon, M.D.
UCSF Fresno
Haifaa Abdulhaq, M.D.

Working Groups and Disease Teams

  • Tissue Core and Database
  • Multiple Myeloma
  • Lymphoma (Including CLL)
  • Acute Leukemia/MDS/MPN
  • Hematopoietic Stem Cell Transplantation and Cellular Therapy